Frontlight ResearchEarly access
Taking people in SwedenPhase 1
Safety of the medicine CV-01 in healthy adults and adults with drug resistant epilepsy
Tests the safety of CV-01 in healthy adults and adults with drug resistant epilepsy.
Key facts
- Who runs it
- Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
- Where
- Moelndal and Uppsala, SwedenSee the 2 sites
- Trial code
- Registry title
- A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 17 Aug 2026
- Expected to end
- 30 Aug 2027
- Type of study
- Interventional
- Record updated
- 8 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and for adults with drug resistant epilepsy to test the safety and effects of CV-01 taken by mouth for 2 weeks.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Drug resistant epilepsy (one group of the trial). Healthy volunteers can also join.
Where in Sweden
- CTC Clinical Trial Consultants ABMoelndal, SwedenTaking people
- CTC Clinical Trial Consultants ABUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Safety of the medicine CV-01 in healthy adults and adults with drug resistant epilepsyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 8 June 2026